Immunotherapies that inhibit the expression of CTLA-4 and PD-1 have been effective in the treatment of various tumors [62–64], and tumor immunotherapy requires sufficient immune cells to infiltrate the tumor microenvironment and sufficient immune checkpoint expression to achieve efficacy [65]. Here, CTLA4 is linked to neoplasm.